Sumitomo Dainippon Pharma Co (DPM) Stock Price & Analysis
DPM Stock Chart & Stats
- Day’s Range
- EUR 10.90 - EUR 11.26
- 52-Week Range
- EUR 6.65 - EUR 18.80
- Previous Close
- EUR 10.96
- Volume
- 0
- Average Volume (3M)
- 25
- Market Cap
- EUR 4.80B
- Enterprise Value
- EUR 791.57B
- Total Cash (Recent Filing)
- EUR 77.76B
- Total Debt (Recent Filing)
- EUR 139.69B
- Price to Earnings (P/E)
- 6.7
- Beta
- 1.29
- Next Earnings
- Jan 29, 2027 (Est.)
- EPS Estimate
- 0.62
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improved Profitability
The return to strong profitability alongside revenue growth indicates meaningful operating recovery after the loss-making period. Gross, EBIT, and net margins provide earnings capacity that can support reinvestment, debt reduction, and improved resilience over the next several quarters.
Deleveraged Balance Sheet
Substantially lower leverage improves financial flexibility and reduces the burden of interest and refinancing obligations. A stronger equity base gives the company more capacity to fund pharmaceutical development, absorb setbacks, and maintain strategic options through the next business cycle.
Rebounded Free Cash Flow
Free cash flow that closely tracks reported profit provides evidence that the current earnings recovery is translating into cash rather than relying mainly on accounting gains. This supports internal funding for research, commercial investment, debt reduction, and other durable capital priorities.
Bears Say
Earnings Volatility
The sharp swing from losses to strong TTM margins reduces confidence that the current earnings level is fully repeatable. Such volatility makes planning and capital allocation more difficult, while one-off or cyclical shocks could again materially weaken reported profitability.
Volatile Cash Conversion
Although recent free cash flow has rebounded, modest operating-cash-flow coverage and a history of weak conversion indicate that cash generation has not been consistently dependable. This can constrain the company’s ability to fund growth and withstand renewed earnings pressure.
Sharp EPS Decline
The steep EPS decline signals that per-share earnings momentum remains materially weaker than the headline recovery in profitability might suggest. Persistent or repeated EPS contraction could limit retained earnings growth and make the company more vulnerable to setbacks in its operating performance.
Sumitomo Dainippon Pharma Co News
DPM FAQ
What was Sumitomo Dainippon Pharma Co’s price range in the past 12 months?
What is Sumitomo Dainippon Pharma Co’s market cap?
When is Sumitomo Dainippon Pharma Co’s upcoming earnings report date?
How were Sumitomo Dainippon Pharma Co’s earnings last quarter?
Is Sumitomo Dainippon Pharma Co overvalued?
Does Sumitomo Dainippon Pharma Co pay dividends?
What is Sumitomo Dainippon Pharma Co’s EPS estimate?
How many shares outstanding does Sumitomo Dainippon Pharma Co have?
What happened to Sumitomo Dainippon Pharma Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sumitomo Dainippon Pharma Co?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Toru Kimura
- Employees
- 3,123
- Website
- www.sumitomo-pharma.com
- Address
- 6-8 Doshomachi 2-chome, Osaka, OS, 541-0045, JP
Sumitomo Dainippon Pharma Co (DPM) Earnings & Revenues
DPM Company Deck
DPM Earnings Call
Earnings Call SentimentNegative
The earnings call highlighted promising developments in the oncology and regenerative medicine pipelines but was overshadowed by significant financial losses, decreased revenue across all segments, and underperformance of key products, leading to a revised downward financial forecast. The call focused on strategic adjustments to address market challenges and improve profitability.
View all DE:DPM earnings summariesDPM Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 3 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 12 | 0 | 0 |
